Published in J Cell Biochem on January 01, 2003
Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis (2009) 1.72
Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci U S A (2004) 1.45
NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget (2011) 1.42
UVB-induced apoptosis drives clonal expansion during skin tumor development. Carcinogenesis (2004) 1.13
c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis. Cancer Biol Ther (2011) 1.04
The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting. Virchows Arch (2005) 0.93
Manganese superoxide dismutase gene dosage affects chromosomal instability and tumor onset in a mouse model of T cell lymphoma. Free Radic Biol Med (2008) 0.89
Recurrence and survival predictive value of phenotypic expression of Bcl-2 varies with tumor stage of colorectal adenocarcinoma. Cancer Biomark (2005) 0.88
Antisense oligonucleotides and all-trans retinoic acid have a synergistic anti-tumor effect on oral squamous cell carcinoma. BMC Cancer (2008) 0.83
The enigmatic roles of caspases in tumor development. Cancers (Basel) (2010) 0.76
Apoptosis induction in Jurkat cells and sCD95 levels in women's sera are related with the risk of developing cervical cancer. BMC Cancer (2008) 0.75
An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science (2008) 4.89
Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A (2010) 3.81
Weak p53 permits senescence during cell cycle arrest. Cell Cycle (2010) 3.33
The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging (Albany NY) (2010) 3.27
Pseudo-DNA damage response in senescent cells. Cell Cycle (2009) 2.93
Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability. Oncogene (2002) 2.52
Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol (2006) 2.47
Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle (2009) 2.43
BMAL1-dependent circadian oscillation of nuclear CLOCK: posttranslational events induced by dimerization of transcriptional activators of the mammalian clock system. Genes Dev (2003) 2.37
Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene (2004) 2.34
Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A. Cell Cycle (2009) 2.22
Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci U S A (2005) 2.14
Structural basis of TLR5-flagellin recognition and signaling. Science (2012) 2.10
Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc Natl Acad Sci U S A (2009) 2.10
Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT. Sci Transl Med (2011) 2.03
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res (2006) 2.03
p53 is a suppressor of inflammatory response in mice. FASEB J (2005) 1.91
Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl Acad Sci U S A (2005) 1.91
Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci U S A (2012) 1.83
Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging (Albany NY) (2012) 1.79
Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget (2011) 1.73
Proteolytic cleavage of the p65-RelA subunit of NF-kappaB during poliovirus infection. J Biol Chem (2005) 1.71
p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proc Natl Acad Sci U S A (2012) 1.71
Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer. Cell Cycle (2009) 1.66
A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion. Cell Rep (2013) 1.58
A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev (2006) 1.58
Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells. Blood (2007) 1.51
Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev (2002) 1.49
Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB. Proc Natl Acad Sci U S A (2009) 1.49
Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor. Cancer Biol Ther (2002) 1.48
p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res (2004) 1.47
New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging (Albany NY) (2012) 1.47
Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci U S A (2004) 1.45
Core circadian protein CLOCK is a positive regulator of NF-κB-mediated transcription. Proc Natl Acad Sci U S A (2012) 1.28
Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res (2006) 1.23
Association of Mycoplasma hominis infection with prostate cancer. Oncotarget (2011) 1.19
Cancer resistance in the blind mole rat is mediated by concerted necrotic cell death mechanism. Proc Natl Acad Sci U S A (2012) 1.18
Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proc Natl Acad Sci U S A (2013) 1.16
Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res (2003) 1.10
p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways. J Biol Chem (2003) 1.10
Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication. PLoS One (2008) 1.10
Identification of granulocyte colony-stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure. J Pharmacol Exp Ther (2012) 1.09
Identification of new drug sensitivity genes using genetic suppressor elements: protein arginine N-methyltransferase mediates cell sensitivity to DNA-damaging agents. Cancer Res (2003) 1.09
p53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res (2007) 1.05
Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys (2011) 1.03
Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. Prostate (2007) 1.03
A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in mice. Cell Cycle (2010) 1.01
Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res (2009) 1.01
Ribonucleotide reductase and thymidylate synthase or exogenous deoxyribonucleosides reduce DNA damage and senescence caused by C-MYC depletion. Aging (Albany NY) (2012) 1.00
Dominant negative form of signal-regulatory protein-alpha (SIRPalpha /SHPS-1) inhibits tumor necrosis factor-mediated apoptosis by activation of NF-kappa B. J Biol Chem (2002) 1.00
Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin. PLoS One (2011) 0.97
Serologically defined colon cancer antigen 3 is necessary for the presentation of TNF receptor 1 on cell surface. DNA Cell Biol (2005) 0.92
CBLB613: a TLR 2/6 agonist, natural lipopeptide of Mycoplasma arginini , as a novel radiation countermeasure. Radiat Res (2011) 0.92
Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53. Oncogene (2003) 0.90
Quinacrine inhibits the epidermal dendritic cell migration initiating T cell-mediated skin inflammation. Eur J Immunol (2007) 0.90
Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state. Cancer Res (2011) 0.90
A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease. J Immunol (2012) 0.89
Poliovirus protein 3A binds and inactivates LIS1, causing block of membrane protein trafficking and deregulation of cell division. Cell Cycle (2005) 0.89
Impact papers on aging in 2009. Aging (Albany NY) (2010) 0.89
Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice. Cancer Prev Res (Phila) (2012) 0.88
Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin. Mol Cancer Ther (2005) 0.87
Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein, BMAL1. Oncotarget (2011) 0.87
Converting p53 from a killer into a healer. Nat Med (2002) 0.86
Bisindolylmaleimide IX facilitates tumor necrosis factor receptor family-mediated cell death and acts as an inhibitor of transcription. J Biol Chem (2002) 0.85
The ability of protein tyrosine phosphatase SHP-1 to suppress NFkappaB can be inhibited by dominant negative mutant of SIRPalpha. DNA Cell Biol (2004) 0.85
A TLR5 agonist inhibits acute renal ischemic failure. J Immunol (2011) 0.84
Selection-subtraction approach (SSA): a universal genetic screening technique that enables negative selection. Proc Natl Acad Sci U S A (2004) 0.84
Falkor, a novel cell growth regulator isolated by a functional genetic screen. Oncogene (2002) 0.84
Functional genetic screening reveals the role of mitochondrial cytochrome b as a mediator of FAS-induced apoptosis. Proc Natl Acad Sci U S A (2008) 0.83
Unstable receptors disappear from cell surface during poliovirus infection. Med Sci Monit (2002) 0.83
Inhibition of encephalomyocarditis virus and poliovirus replication by quinacrine: implications for the design and discovery of novel antiviral drugs. J Virol (2010) 0.83
Combined stimulation of Toll-like receptor 5 and NOD1 strongly potentiates activity of NF-κB, resulting in enhanced innate immune reactions and resistance to Salmonella enterica serovar Typhimurium infection. Infect Immun (2013) 0.83
Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice. Oncotarget (2014) 0.82
Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene (2002) 0.82
Peptides genetically selected for NF-κB activation cooperate with oncogene Ras and model carcinogenic role of inflammation. Proc Natl Acad Sci U S A (2014) 0.81
Genetic suppressor elements in the characterization and identification of tumor suppressor genes. Methods Mol Biol (2003) 0.79
Quercetinase pirin makes poliovirus replication resistant to flavonoid quercetin. DNA Cell Biol (2008) 0.78
The second international conference "genetics of aging and longevity". Aging (Albany NY) (2012) 0.77
ATM is activated in blood monocytes after tumor radiation. Oncotarget (2013) 0.75
Cancer drug discovery: the wisdom of imprecision. Nat Med (2004) 0.75
Cell-based methods for the identification of MYC-inhibitory small molecules. Methods Mol Biol (2013) 0.75